Back

Rivaroxaban treatment strategies reduce not only the first bleeding event, but all (including multiple) bleeding events: A PIONEER Substudy

28 August 2017 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster session 5 - Bleeding and LAA occlusion Atrial fibrillation (AF) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Miss Megan Yee

Boston (United States of America)

8 More presentations in this session

Presentation thumbnail
Professor R. Guo (Wuhan, CN)
Presentation thumbnail
Professor L. Fauchier (Tours, FR)
Abstract Slides
Presentation thumbnail
Professor R. Guo (Wuhan, CN)
Presentation thumbnail
Doctor V. Lekesova (Prague, CZ)
Abstract Slides
Presentation thumbnail
Mr J. Trocio (New York, US)
Abstract

Access the full session

Session thumbnail
Poster session 5 - Bleeding and LAA occlusion

The Event

Event poster

ESC Congress 2017

28 August 2017 14:00 CET
You may be interested in
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
19 July 2023
thumbnail
Congress Presentation
Direct oral anticoagulant rivaroxaban in very old and frail patients: A one-year prospective follow-up of a large-scale cohort (SAFIR-AC)
31 August 2019
thumbnail
Congress Presentation
The incidence of death and risk factors for mortality following major bleeding in patients anticoagulated with factor Xa inhibitors: an observational study in the UK clinical setting (AXIOM UK)
2 September 2024
thumbnail
Congress Presentation
The implication of early bleeding on subsequent clinical outcomes in patients with coronary artery disease and atrial fibrillation: a subgroup analysis of the EPIC-CAD trial
30 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources